The overall scientific goal of this ambitious Program Project is to develop innovative statistical methods for cancer clinical trials that can help to hasten successful introduction of effective new therapies into practice The Computational Resource and Dissemination Core (Core C) will carry out several critical functions related to the implementation and dissemination of the statistical methods for the design and analysis of cancer clinical trials developed in the five research projects. The Core will be tasked with developing, in close collaboration with project investigators, efficient, robust code implementing the statistical methods that can be used for evaluation of the methods in extensive simulation studies and for application of the methods to data compiled by Core B and from other sources. The Core will also be tasked with leading and facilitating, in close collaboration with project investigators, development of robust, reliable, user-friendly, and welldocumented software applications suitable for public dissemination to practitioners involved in the design and analysis of cancer clinical trials. Core C wili adopt best practices for these tasks and provide the necessary information technology and educational infrastructure to disseminate these applications.
Before the new statistical methods for design and analysis of cancer clinical trials to be developed in this Program Project can be adopted for use in cancer research, they must be tested and evaluated, and they must be implemented in user-friendly software accessible to practitioners. Core C will collaborate closely with project investigators to facilitate these efforts.
|Wang, Zhi; Maity, Arnab; Luo, Yiwen et al. (2015) Complete effect-profile assessment in association studies with multiple genetic and multiple environmental factors. Genet Epidemiol 39:122-33|
|Geng, Yuan; Zhang, Hao Helen; Lu, Wenbin (2015) On optimal treatment regimes selection for mean survival time. Stat Med 34:1169-84|
|Liu, Yulun; Chen, Yong; Chu, Haitao (2015) A unification of models for meta-analysis of diagnostic accuracy studies without a gold standard. Biometrics 71:538-47|
|Chen, Qingxia; Zeng, Donglin; Ibrahim, Joseph G et al. (2015) Quantifying the average of the time-varying hazard ratio via a class of transformations. Lifetime Data Anal 21:259-79|
|Viele, Kert; Berry, Scott; Neuenschwander, Beat et al. (2014) Use of historical control data for assessing treatment effects in clinical trials. Pharm Stat 13:41-54|
|Chen, Ming-Hui; Ibrahim, Joseph G; Zeng, Donglin et al. (2014) Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome. Biometrics 70:1003-13|
|Wang, Xin; Zhang, Daowen; Tzeng, Jung-Ying (2014) Pathway-guided identification of gene-gene interactions. Ann Hum Genet 78:478-91|
|Zhang, Jing; Carlin, Bradley P; Neaton, James D et al. (2014) Network meta-analysis of randomized clinical trials: reporting the proper summaries. Clin Trials 11:246-62|
|Lin, Ja-An; Zhu, Hongtu; Mihye, Ahn et al. (2014) Functional-mixed effects models for candidate genetic mapping in imaging genetic studies. Genet Epidemiol 38:680-91|
|Molenberghs, Geert; Kenward, Michael G; Aerts, Marc et al. (2014) On random sample size, ignorability, ancillarity, completeness, separability, and degeneracy: sequential trials, random sample sizes, and missing data. Stat Methods Med Res 23:11-41|
Showing the most recent 10 out of 133 publications